Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study
Copyright policy )Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study
Cysticercosis is a parasitic disease that frequently involves the human central nervous system (CNS), and current treatment options are limited. Oxfendazole, a veterinary medicine belonging to the benzimidazole family of anthelmintic drugs, has demonstrated substantial activity against the tissue stages of Taenia solium and has potential to be developed as an effective therapy for neurocysticercosis.
- Johns Hopkins University United States
- National Institute of Allergy and Infectious Diseases United States
- National University of San Marcos Peru
- University of Iowa United States
- National Institutes of Health United States
Male, double blind procedure, drug safety, ultra performance liquid chromatography, limit of quantitation, phase 1 clinical trial, https://purl.org/pe-repo/ocde/ford#3.01.05, Clinical pharmacokinetics, diarrhea, Administration, Oral, volume of distribution, aspartate aminotransferase, Anthelmintic agent, drug dose regimen, adult, single drug dose, Middle Aged, Healthy Volunteers, sore throat, unclassified drug, female, leukocytosis, priority journal, oxfendazole glucuronide, Female, First-in-human study, eosinophilia, bicarbonate blood level, Half-Life, Adult, oxfendazole, drug exposure, pharmacokinetic parameters, side effect, Adolescent, area under the curve, https://purl.org/pe-repo/ocde/ford#3.03.08, Biological Availability, bicarbonate, urinary excretion, oxfendazole sulfate, Article, Young Adult, male, Double-Blind Method, first in human study, activated partial thromboplastin time, neutropenia, no-observed-adverse-effect level, Humans, controlled study, human, normal human, arthralgia, Oxfendazole, fenbendazole, liquid chromatography-mass spectrometry, elimination half-life, viral gastroenteritis, Dose-Response Relationship, Drug, Cysticercosis, maximum plasma concentration, oxfendazole sulfone, leukopenia, drug bioavailability, renal clearance, major clinical study, drug metabolism, flatulence, plasma half life, intestine absorption, time to maximum plasma concentration, elimination rate constant, randomized controlled trial, drug solubility, PR interval, drug metabolite, Benzimidazoles, drug dose escalation, drug tolerability, plasma concentration-time curve
Male, double blind procedure, drug safety, ultra performance liquid chromatography, limit of quantitation, phase 1 clinical trial, https://purl.org/pe-repo/ocde/ford#3.01.05, Clinical pharmacokinetics, diarrhea, Administration, Oral, volume of distribution, aspartate aminotransferase, Anthelmintic agent, drug dose regimen, adult, single drug dose, Middle Aged, Healthy Volunteers, sore throat, unclassified drug, female, leukocytosis, priority journal, oxfendazole glucuronide, Female, First-in-human study, eosinophilia, bicarbonate blood level, Half-Life, Adult, oxfendazole, drug exposure, pharmacokinetic parameters, side effect, Adolescent, area under the curve, https://purl.org/pe-repo/ocde/ford#3.03.08, Biological Availability, bicarbonate, urinary excretion, oxfendazole sulfate, Article, Young Adult, male, Double-Blind Method, first in human study, activated partial thromboplastin time, neutropenia, no-observed-adverse-effect level, Humans, controlled study, human, normal human, arthralgia, Oxfendazole, fenbendazole, liquid chromatography-mass spectrometry, elimination half-life, viral gastroenteritis, Dose-Response Relationship, Drug, Cysticercosis, maximum plasma concentration, oxfendazole sulfone, leukopenia, drug bioavailability, renal clearance, major clinical study, drug metabolism, flatulence, plasma half life, intestine absorption, time to maximum plasma concentration, elimination rate constant, randomized controlled trial, drug solubility, PR interval, drug metabolite, Benzimidazoles, drug dose escalation, drug tolerability, plasma concentration-time curve
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).32 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!